Ebola Outbreak in Democratic Republic of Congo Causes Thousands of Deaths

A severe outbreak of the Bundibugyo Ebola virus in the Democratic Republic of Congo has resulted in thousands of deaths since beginning in mid May. Reports on the scale of the crisis vary. One source states that more than 3,000 people have died, while another reports that the World Health Organization registered nearly 5,800 infections and more than 2,700 deaths across at least five provinces by late August. This outbreak is described as the largest the country has ever experienced.

Medical professionals are highlighting significant challenges in treating the disease, particularly among children. Doctors Without Borders reported in the medical journal The Lancet that the mortality rate for children under five exceeds 60 percent. Experts note that children are harder to diagnose because early symptoms resemble other illnesses and they often cannot be accompanied by caregivers into treatment centers. Furthermore, a gap in pediatric research exists because children have different metabolisms and pharmacokinetics than adults. While an experimental antiviral drug called obeldesivir is being studied, children weighing less than 20 kilograms are currently excluded from the study. These patients must rely on remdesivir, which requires a 10 day course of intravenous infusions that is difficult to administer during an outbreak.

Beyond medical limitations, the response is hindered by a lack of trust. Some patients avoid treatment centers because they associate them with death, especially when patients arrive too late to be saved. Experts argue that the fight against Ebola requires not only vaccines and tests but also the cultivation of trust within affected communities to ensure people seek help early. In a separate incident in Berlin, an American doctor and his family were treated prophylactically with an experimental antibody drug called MBP134 after the doctor contracted the virus while treating patients. The family remained healthy, providing a small but valuable data point regarding the drug's tolerance in children.